{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:43:39Z","timestamp":1788921819079,"version":"build-2803163510"},"reference-count":104,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>The discovery and development of erythropoiesis-stimulating agents was a journey lasting more than a century, leading to the cloning and approval of recombinant human erythropoietin (rHuEpo). This was an impressive clinical advance, providing the possibility of correcting the symptoms associated with anaemia in chronic kidney disease. Associated iron use was needed to produce new haemoglobin-containing blood red cells. Partial anaemia correction became the standard of care since trials aiming for near-normal haemoglobin levels showed a higher risk of adverse cardiovascular events. Hoping to reduce the cardiovascular risks, a new category of drugs was developed and tested. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are small molecules than can be formulated into orally active pills. They simulate reduced tissue oxygen pressure, thus stimulating the production of endogenous erythropoietin (Epo) by the kidneys and liver. Clinical trials with these compounds demonstrated that HIF-PHIs are at least as effective as rHuEpo in treating or correcting anaemia in non-dialysis and dialysis patients. Trials with HIF-PHIs did not demonstrate superiority in safety outcomes and in some trials, outcomes were worse. There was also a focus on oral delivery, a possible beneficial iron-sparing effect and the ability to overcome Epo resistance in inflamed patients. A negative effect is possible iron depletion, which may explain adverse outcomes.<\/jats:p>","DOI":"10.1093\/ckj\/sfad105","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T12:22:53Z","timestamp":1692188573000},"page":"1563-1579","source":"Crossref","is-referenced-by-count":15,"title":["The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors"],"prefix":"10.1093","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7505-261X","authenticated-orcid":false,"given":"Francesco","family":"Locatelli","sequence":"first","affiliation":[{"name":"Department of Nephrology and Dialysis, Alessandro Manzoni Hospital , Lecco , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Del Vecchio","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Sant\u2019 Anna Hospital, ASST Lariana , Como , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Elliott","sequence":"additional","affiliation":[{"name":"Elliott Consulting , Thousand Oaks, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"2023092902520848400_bib1","volume-title":"De l'anemie des altitudes et de l'anemie en general dans ses rapports avec la pression del l'atmosphere","author":"Jourdanet","year":"1863"},{"key":"2023092902520848400_bib2","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1016\/S0021-9258(19)63387-9","article-title":"Purification of human erythropoietin","volume":"252","author":"Miyake","year":"1977","journal-title":"J Biol Chem"},{"key":"2023092902520848400_bib3","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1073\/pnas.82.22.7580","article-title":"Cloning and expression of the human erythropoietin gene","volume":"82","author":"Lin","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023092902520848400_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","article-title":"Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial","volume":"316","author":"Eschbach","year":"1987","journal-title":"N Engl J Med"},{"key":"2023092902520848400_bib5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(89)90698-3","article-title":"Recombinant human erythropoietin treatment in patients on maintenance home haemodialysis","volume":"334","author":"Winearls","year":"1989","journal-title":"Lancet"},{"key":"2023092902520848400_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ki.1989.18","article-title":"The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin","volume":"35","author":"Eschbach","year":"1989","journal-title":"Kidney Int"},{"key":"2023092902520848400_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1387-2656(04)10008-2","article-title":"Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge","volume":"10","author":"Smalling","year":"2004","journal-title":"Biotechnol Annu Rev"},{"key":"2023092902520848400_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/ndt\/gfg1091","article-title":"Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin","volume":"18","author":"Casadevall","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902520848400_bib9","first-page":"931","article-title":"Discovery of AranespTM: a novel erythropoiesis stimulating protein with an increased serum half-life","volume":"11","author":"Elliott","year":"2001","journal-title":"Glycobiology"},{"key":"2023092902520848400_bib10","first-page":"436","article-title":"CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia","volume":"4","author":"Macdougall","year":"2005","journal-title":"Curr Hematol Rep"},{"key":"2023092902520848400_bib11","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(07)61599-2","article-title":"Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA)","volume":"370","author":"Levin","year":"2007","journal-title":"Lancet"},{"key":"2023092902520848400_bib12","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.exphem.2006.05.012","article-title":"Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia","volume":"34","author":"Fan","year":"2006","journal-title":"Exp Hematol"},{"key":"2023092902520848400_bib13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1586\/ehm.09.15","article-title":"Hematide\u2122 for the treatment of chronic kidney disease-related anemia","volume":"2","author":"Locatelli","year":"2009","journal-title":"Expert Rev Hematol"},{"key":"2023092902520848400_bib14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1203166","article-title":"Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis","volume":"368","author":"Macdougall","year":"2013","journal-title":"N Engl J Med"},{"key":"2023092902520848400_bib15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"2023092902520848400_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMc076523","article-title":"The normal hematocrit study\u2014follow-up","volume":"358","author":"Besarab","year":"2008","journal-title":"N Engl J Med"},{"key":"2023092902520848400_bib17","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"2023092902520848400_bib18","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"2023092902520848400_bib19","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"2023092902520848400_bib20","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1046\/j.1523-1755.2000.00289.x","article-title":"Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy","volume":"58","author":"Foley","year":"2000","journal-title":"Kidney Int"},{"key":"2023092902520848400_bib21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.ajkd.2012.07.014","article-title":"Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis","volume":"61","author":"Koulouridis","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2023092902520848400_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","article-title":"Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease","volume":"153","author":"Palmer","year":"2010","journal-title":"Ann Intern Med"},{"key":"2023092902520848400_bib23","doi-asserted-by":"crossref","first-page":"c95","DOI":"10.1159\/000345158","article-title":"Treatment of anaemia with erythropoiesis-stimulating agents in patients with chronic kidney disease does not lower mortality and may increase cardiovascular risk: a meta-analysis","volume":"121","author":"Vinhas","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"2023092902520848400_bib24","first-page":"CD010590","article-title":"Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis","volume":"2","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2023092902520848400_bib25","first-page":"CD003266","article-title":"Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis","volume":"2016","author":"Cody","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2023092902520848400_bib26","first-page":"CD010590","article-title":"Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis","volume":"2","author":"Chung","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2023092902520848400_bib27","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"2023092902520848400_bib28","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2215\/CJN.01380219","article-title":"Cardiovascular safety and all-cause mortality of methoxy polyethylene glycol-epoetin beta and other erythropoiesis-stimulating agents in anemia of CKD: a randomized noninferiority trial","volume":"14","author":"Locatelli","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023092902520848400_bib29","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/ckj\/sfaa054","article-title":"Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis","volume":"13","author":"Evans","year":"2020","journal-title":"Clin Kidney J"},{"key":"2023092902520848400_bib30","first-page":"279","article-title":"Kidney Disease: Improving Global Outcomes anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2023092902520848400_bib31","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902520848400_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12882-017-0438-4","article-title":"Erythropoiesis stimulating agents and reno-protection: a meta-analysis","volume":"18","author":"Elliott","year":"2017","journal-title":"BMC Nephrol"},{"key":"2023092902520848400_bib33","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/jcpt.13385","article-title":"Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta-analysis including 13,146 patients","volume":"46","author":"Chen","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"2023092902520848400_bib34","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023092902520848400_bib35","doi-asserted-by":"crossref","first-page":"C1362","DOI":"10.1152\/ajpcell.1995.268.6.C1362","article-title":"Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents","volume":"268","author":"Gleadle","year":"1995","journal-title":"Am J Physiol Cell Physiol"},{"key":"2023092902520848400_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/15216540252774757","article-title":"Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing","volume":"52","author":"Mole","year":"2001","journal-title":"IUBMB Life"},{"key":"2023092902520848400_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","article-title":"Regulation of erythropoiesis by hypoxia-inducible factors","volume":"27","author":"Haase","year":"2013","journal-title":"Blood Rev"},{"key":"2023092902520848400_bib38","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1172\/JCI200318181","article-title":"HIF hydroxylation and the mammalian oxygen-sensing pathway","volume":"111","author":"Safran","year":"2003","journal-title":"J Clin Invest"},{"key":"2023092902520848400_bib39","doi-asserted-by":"crossref","first-page":"e13768","DOI":"10.1111\/apha.13768","article-title":"Fate-mapping of erythropoietin-producing cells in mouse models of hypoxaemia and renal tissue remodelling reveals repeated recruitment and persistent functionality","volume":"234","author":"Dahl","year":"2022","journal-title":"Acta Physiol (Oxf)"},{"key":"2023092902520848400_bib40","doi-asserted-by":"crossref","first-page":"e13826","DOI":"10.1111\/apha.13826","article-title":"EPO synthesis induced by HIF-PHD inhibition is dependent on myofibroblast transdifferentiation and colocalizes with non-injured nephron segments in murine kidney fibrosis","volume":"235","author":"Kobayashi","year":"2022","journal-title":"Acta Physiol (Oxf)"},{"key":"2023092902520848400_bib41","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902520848400_bib42","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med"},{"key":"2023092902520848400_bib43","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med"},{"key":"2023092902520848400_bib44","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"2023092902520848400_bib45","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.16191020","article-title":"Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials","volume":"16","author":"Provenzano","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023092902520848400_bib46","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s40265-022-01783-3","article-title":"Evolving strategies in the treatment of anaemia in chronic kidney disease: the HIF-prolyl hydroxylase inhibitors","volume":"82","author":"Locatelli","year":"2022","journal-title":"Drugs"},{"key":"2023092902520848400_bib47","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamacardio.2019.1739","article-title":"Differences in clinical profile and outcomes of low iron storage vs defective iron utilization in patients with heart failure: results from the DEFINE-HF and BIOSTAT-CHF studies","volume":"4","author":"Grote Beverborg","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2023092902520848400_bib48","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"2023092902520848400_bib49","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jacc.2011.04.040","article-title":"Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival","volume":"58","author":"Okonko","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2023092902520848400_bib50","doi-asserted-by":"crossref","first-page":"107602962211038","DOI":"10.1177\/10760296221103867","article-title":"The association between mean corpuscular hemoglobin concentration and prognosis in patients with acute pulmonary embolism: a retrospective cohort study","volume":"28","author":"Ruan","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"2023092902520848400_bib51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurjhf\/hfp179","article-title":"Red blood cell distribution width and 1-year mortality in acute heart failure","volume":"12","author":"van Kimmenade","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2023092902520848400_bib52","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/chf.12010","article-title":"Prognostic implications of relative hypochromia in ambulatory patients with chronic systolic heart failure","volume":"19","author":"Simbaqueba","year":"2013","journal-title":"Congest Heart Fail"},{"key":"2023092902520848400_bib53","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/eurjhf\/hft068","article-title":"The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study 3324","volume":"15","author":"Van Craenenbroeck","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2023092902520848400_bib54","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1542\/peds.2007-0502","article-title":"Association between iron-deficiency anemia and stroke in young children","volume":"120","author":"Maguire","year":"2007","journal-title":"Pediatrics"},{"key":"2023092902520848400_bib55","first-page":"484","article-title":"Cerebral vascular accidents in cyanotic congenital heart disease","volume":"125","author":"Cottrill","year":"1973","journal-title":"Am J Dis Child"},{"key":"2023092902520848400_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jocn.2018.12.005","article-title":"Abnormal red blood cell indices increase the risk of arterial ischemic stroke in children","volume":"62","author":"Khongkhatithum","year":"2019","journal-title":"J Clin Neurosci"},{"key":"2023092902520848400_bib57","doi-asserted-by":"crossref","first-page":"e88812","DOI":"10.1371\/journal.pone.0088812","article-title":"Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron deficiency and platelets","volume":"9","author":"Shovlin","year":"2014","journal-title":"PLoS One"},{"key":"2023092902520848400_bib58","doi-asserted-by":"crossref","first-page":"e82952","DOI":"10.1371\/journal.pone.0082952","article-title":"Association between ischemic stroke and iron-deficiency anemia: a population-based study","volume":"8","author":"Chang","year":"2013","journal-title":"PLoS One"},{"key":"2023092902520848400_bib59","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1681\/ASN.2016040401","article-title":"Fibroblast growth factor 23 and the risk of infection-related hospitalization in older adults","volume":"28","author":"Nowak","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2023092902520848400_bib60","doi-asserted-by":"crossref","first-page":"107602962211038","DOI":"10.1177\/10760296221103867","article-title":"The association between mean corpuscular hemoglobin concentration and prognosis in patients with acute pulmonary embolism: a retrospective cohort study","volume":"28","author":"Ruan","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"2023092902520848400_bib61","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ckj\/sfx043","article-title":"Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions","volume":"10","author":"Macdougall","year":"2017","journal-title":"Clin Kidney J"},{"key":"2023092902520848400_bib62","doi-asserted-by":"crossref","first-page":"R152","DOI":"10.1152\/ajpregu.00070.2021","article-title":"Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial","volume":"321","author":"Breenfeldt Andersen","year":"2021","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2023092902520848400_bib63","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/ajh.26644","article-title":"Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease","volume":"97","author":"Koury","year":"2022","journal-title":"Am J Hematol"},{"key":"2023092902520848400_bib64","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.120.265181","article-title":"Nonclinical characterization of the hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat, a novel treatment of anemia of chronic kidney disease","volume":"374","author":"Del Balzo","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"2023092902520848400_bib65","doi-asserted-by":"crossref","first-page":"667117","DOI":"10.3389\/fmed.2021.667117","article-title":"Effects of roxadustat on the anemia and iron metabolism of patients undergoing peritoneal dialysis","volume":"8","author":"Hirai","year":"2021","journal-title":"Front Med"},{"key":"2023092902520848400_bib66","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2023092902520848400_bib67","first-page":"364","article-title":"Physiological and pharmacodynamic considerations for route of EPO administration","volume":"20","author":"Besarab","year":"2000","journal-title":"Semin Nephrol"},{"key":"2023092902520848400_bib68","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s11255-020-02693-7","article-title":"The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review","volume":"53","author":"Qie","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"2023092902520848400_bib69","doi-asserted-by":"crossref","first-page":"779694","DOI":"10.3389\/fphar.2022.779694","article-title":"The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2023092902520848400_bib70","doi-asserted-by":"crossref","first-page":"4764254","DOI":"10.1155\/2022\/4764254","article-title":"Effect of roxadustat on factors associated with renal fibrosis and efficacy","volume":"2022","author":"Zheng","year":"2022","journal-title":"Comput Math Methods Med"},{"key":"2023092902520848400_bib71","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/ckj\/sfac271","article-title":"The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic review and meta-analysis","volume":"16","author":"Takkavatakarn","year":"2023","journal-title":"Clin Kidney J"},{"key":"2023092902520848400_bib72","doi-asserted-by":"crossref","first-page":"7334","DOI":"10.1038\/s41467-021-27562-4","article-title":"EpoR stimulates rapid cycling and larger red cells during mouse and human erythropoiesis","volume":"12","author":"Hidalgo","year":"2021","journal-title":"Nat Commun"},{"key":"2023092902520848400_bib73","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2215\/CJN.01670408","article-title":"Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988\u20132004","volume":"4","author":"Fishbane","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023092902520848400_bib74","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12882-017-0745-9","article-title":"Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"18","author":"Robinson","year":"2017","journal-title":"BMC Nephrol"},{"key":"2023092902520848400_bib75","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.34067\/KID.0001442022","article-title":"Changes in iron availability with roxadustat in nondialysis- and dialysis-dependent patients with anemia of CKD","volume":"3","author":"Pergola","year":"2022","journal-title":"Kidney360"},{"key":"2023092902520848400_bib76","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902520848400_bib77","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"issue":"(Suppl 7)","key":"2023092902520848400_bib78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/ndt\/16.suppl_7.25","article-title":"Hyporesponsiveness to recombinant human erythropoietin","volume":"16","author":"Drueke","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902520848400_bib79","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1161\/CIRCULATIONAHA.111.030411","article-title":"Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) experience","volume":"124","author":"Skali","year":"2011","journal-title":"Circulation"},{"key":"2023092902520848400_bib80","first-page":"93","article-title":"New perspectives on the molecular basis of the interaction between oxygen homeostasis and iron metabolism","volume":"3","author":"Recalcati","year":"2015","journal-title":"Hypoxia (Auckl)"},{"key":"2023092902520848400_bib81","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MBC.0b013e32835bfdb9","article-title":"Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?","volume":"24","author":"Zangari","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2023092902520848400_bib82","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1055\/s-2006-939441","article-title":"Vascular complications in Chuvash polycythemia","volume":"32","author":"Gordeuk","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"2023092902520848400_bib83","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12959-019-0205-9","article-title":"Hypoxia and HIF activation as a possible link between sepsis and thrombosis","volume":"17","author":"Evans","year":"2019","journal-title":"Thromb J"},{"key":"2023092902520848400_bib84","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1371\/journal.pmed.0030290","article-title":"Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology","volume":"3","author":"Smith","year":"2006","journal-title":"PLoS Med"},{"key":"2023092902520848400_bib85","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jvs.2013.02.240","article-title":"Hypoxia-inducible factor pathway and diseases of the vascular wall","volume":"58","author":"Lim","year":"2013","journal-title":"J Vasc Surg"},{"key":"2023092902520848400_bib86","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1152\/japplphysiol.00643.2013","article-title":"HIF and pulmonary vascular responses to hypoxia","volume":"116","author":"Shimoda","year":"2014","journal-title":"J Appl Physiol"},{"key":"2023092902520848400_bib87","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1113\/jphysiol.2008.160960","article-title":"The increase in pulmonary arterial pressure caused by hypoxia depends on iron status","volume":"586","author":"Smith","year":"2008","journal-title":"J Physiol"},{"key":"2023092902520848400_bib88","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1001\/jama.2009.1404","article-title":"Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials","volume":"302","author":"Smith","year":"2009","journal-title":"JAMA"},{"key":"2023092902520848400_bib89","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"2023092902520848400_bib90","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"2023092902520848400_bib91","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"key":"2023092902520848400_bib92","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/nep.13835","article-title":"Recommendations by the Asian Pacific Society of Nephrology (APSN) on the appropriate use of HIF-PH inhibitors","volume":"26","author":"Yap","year":"2021","journal-title":"Nephrology"},{"key":"2023092902520848400_bib93","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1681\/ASN.2022040413","article-title":"Hypoxia-inducible factor-prolyl hydroxyl domain inhibitors: from theoretical superiority to clinical noninferiority compared with current ESAs?","volume":"33","author":"Locatelli","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2023092902520848400_bib94","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1093\/ckj\/sfab134","article-title":"Roxadustat in the treatment of a hemodialysis patient with anti-erythropoietin antibody-mediated pure red cell aplasia","volume":"14","author":"Xu","year":"2021","journal-title":"Clin Kidney J"},{"key":"2023092902520848400_bib95","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023092902520848400_bib96","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902520848400_bib97","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2023092902520848400_bib98","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902520848400_bib99","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A randomized trial of roxadustat in anemia of kidney failure: SIERRAS Study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023092902520848400_bib100","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES)","volume":"38","author":"Csiky","year":"2021","journal-title":"Adv Ther"},{"key":"2023092902520848400_bib101","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES Study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2023092902520848400_bib102","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"2023092902520848400_bib103","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2215\/CJN.00550122","article-title":"Three times weekly dosing of daprodustat versus conventional epoetin for treatment of anemia in hemodialysis patients: ASCEND-TD: a phase 3 randomized, double-blind, noninferiority trial","volume":"17","author":"Coyne","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023092902520848400_bib104","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/jamainternmed.2022.0605","article-title":"Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: a randomized clinical trial","volume":"182","author":"Singh","year":"2022","journal-title":"JAMA Intern Med"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad105\/51176996\/sfad105.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/10\/1563\/51788608\/sfad105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/10\/1563\/51788608\/sfad105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T02:55:38Z","timestamp":1695956138000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/10\/1563\/7244733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":104,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,8,17]]},"published-print":{"date-parts":[[2023,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad105","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,8,17]]}}}